PubMed:7721831
Annnotations
GlyCosmos6-Glycan-Motif-Image
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 483-494 | Glycan_Motif | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G43702JT |
T2 | 840-849 | Glycan_Motif | denotes | galactose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G68158BT|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE |
T4 | 2057-2068 | Glycan_Motif | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G43702JT |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-63 | Sentence | denotes | Identification of a novel glycosaminoglycan core-like molecule. |
T2 | 64-67 | Sentence | denotes | II. |
T3 | 68-129 | Sentence | denotes | Alpha-GalNAc-capped xylosides can be made by many cell types. |
T4 | 130-179 | Sentence | denotes | The accompanying article (Manzi, A., Salimath, P. |
T5 | 180-193 | Sentence | denotes | V., Spiro, R. |
T6 | 194-208 | Sentence | denotes | C., Keifer, P. |
T7 | 209-227 | Sentence | denotes | A., and Freeze, H. |
T8 | 228-240 | Sentence | denotes | H. (1995) J. |
T9 | 241-246 | Sentence | denotes | Biol. |
T10 | 247-252 | Sentence | denotes | Chem. |
T11 | 253-414 | Sentence | denotes | 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU). |
T12 | 415-691 | Sentence | denotes | The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-Gal-NAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains. |
T13 | 692-829 | Sentence | denotes | In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides. |
T14 | 830-1001 | Sentence | denotes | The [6-3H]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc. |
T15 | 1002-1116 | Sentence | denotes | Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. |
T16 | 1117-1322 | Sentence | denotes | The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. |
T17 | 1323-1586 | Sentence | denotes | This novel oligosaccharide accounts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 microM Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%. |
T18 | 1587-1695 | Sentence | denotes | In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. |
T19 | 1696-1871 | Sentence | denotes | Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact. |
T20 | 1872-1979 | Sentence | denotes | This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis. |
T21 | 1980-2188 | Sentence | denotes | Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation. |
T1 | 0-63 | Sentence | denotes | Identification of a novel glycosaminoglycan core-like molecule. |
T2 | 64-67 | Sentence | denotes | II. |
T3 | 68-129 | Sentence | denotes | Alpha-GalNAc-capped xylosides can be made by many cell types. |
T4 | 130-179 | Sentence | denotes | The accompanying article (Manzi, A., Salimath, P. |
T5 | 180-193 | Sentence | denotes | V., Spiro, R. |
T6 | 194-208 | Sentence | denotes | C., Keifer, P. |
T7 | 209-227 | Sentence | denotes | A., and Freeze, H. |
T8 | 228-240 | Sentence | denotes | H. (1995) J. |
T9 | 241-246 | Sentence | denotes | Biol. |
T10 | 247-252 | Sentence | denotes | Chem. |
T11 | 253-414 | Sentence | denotes | 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU). |
T12 | 415-691 | Sentence | denotes | The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-Gal-NAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains. |
T13 | 692-829 | Sentence | denotes | In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides. |
T14 | 830-1001 | Sentence | denotes | The [6-3H]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc. |
T15 | 1002-1116 | Sentence | denotes | Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. |
T16 | 1117-1322 | Sentence | denotes | The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. |
T17 | 1323-1586 | Sentence | denotes | This novel oligosaccharide accounts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 microM Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%. |
T18 | 1587-1695 | Sentence | denotes | In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. |
T19 | 1696-1871 | Sentence | denotes | Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact. |
T20 | 1872-1979 | Sentence | denotes | This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis. |
T21 | 1980-2188 | Sentence | denotes | Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation. |
GlyCosmos6-Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 483-494 | https://glytoucan.org/Structures/Glycans/G43702JT | denotes | chondroitin |
T2 | 840-849 | https://glytoucan.org/Structures/Glycans/G65889KE | denotes | galactose |
T3 | 840-849 | https://glytoucan.org/Structures/Glycans/G68158BT | denotes | galactose |
T4 | 2057-2068 | https://glytoucan.org/Structures/Glycans/G43702JT | denotes | chondroitin |
Glycosmos6-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 483-494 | http://www.glycoepitope.jp/epitopes/EP0081 | denotes | chondroitin |
T2 | 668-683 | http://www.glycoepitope.jp/epitopes/EP0086 | denotes | heparan sulfate |
T3 | 2057-2068 | http://www.glycoepitope.jp/epitopes/EP0081 | denotes | chondroitin |
NGLY1-deficiency
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-NGLY1-deficiency-B_T1 | 658-664 | chem:24139 | denotes | GlcNAc |
mondo_disease
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 335-343 | Disease | denotes | melanoma | http://purl.obolibrary.org/obo/MONDO_0005105 |
T2 | 739-745 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T3 | 1416-1424 | Disease | denotes | melanoma | http://purl.obolibrary.org/obo/MONDO_0005105 |
Glycan-GlyCosmos
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 74-80 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T2 | 483-494 | Glycan | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT |
T3 | 561-568 | Glycan | denotes | Gal-NAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T4 | 626-632 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T5 | 805-811 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T6 | 905-911 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T7 | 978-984 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T8 | 1279-1285 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T9 | 1732-1738 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T10 | 1997-2003 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T11 | 2057-2068 | Glycan | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT |
T21 | 668-683 | Glycan | denotes | heparan sulfate | https://api.glycosmos.org/wurcs2image/latest/png/binary/G17927IW |
GlyCosmos-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 483-494 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | chondroitin | http://www.glycoepitope.jp/epitopes/EP0081 |
T2 | 668-683 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | heparan sulfate | http://www.glycoepitope.jp/epitopes/EP0086 |
T3 | 2057-2068 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | chondroitin | http://www.glycoepitope.jp/epitopes/EP0081 |
GlyCosmos15-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 335-343 | Phenotype | denotes | melanoma | HP:0002861 |
T2 | 739-745 | Phenotype | denotes | cancer | HP:0002664 |
T3 | 1416-1424 | Phenotype | denotes | melanoma | HP:0002861 |
GlyCosmos15-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 335-343 | Disease | denotes | melanoma | http://purl.obolibrary.org/obo/MONDO_0005105 |
T2 | 739-745 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T3 | 1416-1424 | Disease | denotes | melanoma | http://purl.obolibrary.org/obo/MONDO_0005105 |
GlyCosmos15-NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 329-334 | OrganismTaxon | denotes | human | 9606 |
T2 | 733-738 | OrganismTaxon | denotes | human | 9606 |
T3 | 761-776 | OrganismTaxon | denotes | Chinese hamster | 10029 |
T4 | 933-946 | OrganismTaxon | denotes | Helix pomatia | 6536 |
T5 | 1410-1415 | OrganismTaxon | denotes | human | 9606 |
T6 | 1429-1444 | OrganismTaxon | denotes | Chinese hamster | 10029 |
GlyCosmos15-CL
Id | Subject | Object | Predicate | Lexical cue | cl_id |
---|---|---|---|---|---|
T1 | 739-750 | Cell | denotes | cancer cell | http://purl.obolibrary.org/obo/CL:0001064 |
GlyCosmos15-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 777-782 | Body_part | denotes | ovary | http://purl.obolibrary.org/obo/UBERON_0000992 |
T2 | 933-938 | Body_part | denotes | Helix | http://purl.obolibrary.org/obo/UBERON_0002488 |
T3 | 1445-1450 | Body_part | denotes | ovary | http://purl.obolibrary.org/obo/UBERON_0000992 |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-63 | Sentence | denotes | Identification of a novel glycosaminoglycan core-like molecule. |
T2 | 64-67 | Sentence | denotes | II. |
T3 | 68-129 | Sentence | denotes | Alpha-GalNAc-capped xylosides can be made by many cell types. |
T4 | 130-179 | Sentence | denotes | The accompanying article (Manzi, A., Salimath, P. |
T5 | 180-193 | Sentence | denotes | V., Spiro, R. |
T6 | 194-208 | Sentence | denotes | C., Keifer, P. |
T7 | 209-227 | Sentence | denotes | A., and Freeze, H. |
T8 | 228-240 | Sentence | denotes | H. (1995) J. |
T9 | 241-246 | Sentence | denotes | Biol. |
T10 | 247-252 | Sentence | denotes | Chem. |
T11 | 253-414 | Sentence | denotes | 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU). |
T12 | 415-691 | Sentence | denotes | The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-Gal-NAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains. |
T13 | 692-829 | Sentence | denotes | In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides. |
T14 | 830-1001 | Sentence | denotes | The [6-3H]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc. |
T15 | 1002-1116 | Sentence | denotes | Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. |
T16 | 1117-1322 | Sentence | denotes | The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. |
T17 | 1323-1586 | Sentence | denotes | This novel oligosaccharide accounts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 microM Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%. |
T18 | 1587-1695 | Sentence | denotes | In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. |
T19 | 1696-1871 | Sentence | denotes | Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact. |
T20 | 1872-1979 | Sentence | denotes | This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis. |
T21 | 1980-2188 | Sentence | denotes | Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation. |
T1 | 0-63 | Sentence | denotes | Identification of a novel glycosaminoglycan core-like molecule. |
T2 | 64-67 | Sentence | denotes | II. |
T3 | 68-129 | Sentence | denotes | Alpha-GalNAc-capped xylosides can be made by many cell types. |
T4 | 130-179 | Sentence | denotes | The accompanying article (Manzi, A., Salimath, P. |
T5 | 180-193 | Sentence | denotes | V., Spiro, R. |
T6 | 194-208 | Sentence | denotes | C., Keifer, P. |
T7 | 209-227 | Sentence | denotes | A., and Freeze, H. |
T8 | 228-240 | Sentence | denotes | H. (1995) J. |
T9 | 241-246 | Sentence | denotes | Biol. |
T10 | 247-252 | Sentence | denotes | Chem. |
T11 | 253-414 | Sentence | denotes | 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU). |
T12 | 415-691 | Sentence | denotes | The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-Gal-NAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains. |
T13 | 692-829 | Sentence | denotes | In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides. |
T14 | 830-1001 | Sentence | denotes | The [6-3H]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc. |
T15 | 1002-1116 | Sentence | denotes | Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. |
T16 | 1117-1322 | Sentence | denotes | The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. |
T17 | 1323-1586 | Sentence | denotes | This novel oligosaccharide accounts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 microM Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%. |
T18 | 1587-1695 | Sentence | denotes | In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. |
T19 | 1696-1871 | Sentence | denotes | Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact. |
T20 | 1872-1979 | Sentence | denotes | This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis. |
T21 | 1980-2188 | Sentence | denotes | Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation. |
GlyCosmos15-Sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-63 | Sentence | denotes | Identification of a novel glycosaminoglycan core-like molecule. |
T2 | 64-67 | Sentence | denotes | II. |
T3 | 68-129 | Sentence | denotes | Alpha-GalNAc-capped xylosides can be made by many cell types. |
T4 | 130-414 | Sentence | denotes | The accompanying article (Manzi, A., Salimath, P. V., Spiro, R. C., Keifer, P. A., and Freeze, H. H. (1995) J. Biol. Chem. 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU). |
T5 | 415-691 | Sentence | denotes | The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-Gal-NAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains. |
T6 | 692-829 | Sentence | denotes | In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides. |
T7 | 830-1116 | Sentence | denotes | The [6-3H]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc. Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. |
T8 | 1117-1322 | Sentence | denotes | The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. |
T9 | 1323-1586 | Sentence | denotes | This novel oligosaccharide accounts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 microM Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%. |
T10 | 1587-1695 | Sentence | denotes | In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. |
T11 | 1696-1871 | Sentence | denotes | Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact. |
T12 | 1872-1979 | Sentence | denotes | This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis. |
T13 | 1980-2188 | Sentence | denotes | Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation. |
GlyCosmos15-Glycan
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 74-80 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T2 | 483-494 | Glycan | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT |
T3 | 561-568 | Glycan | denotes | Gal-NAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T4 | 626-632 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T5 | 805-811 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T6 | 905-911 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T7 | 978-984 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T8 | 1279-1285 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T9 | 1732-1738 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T10 | 1997-2003 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T11 | 2057-2068 | Glycan | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT |
T21 | 668-683 | Glycan | denotes | heparan sulfate | https://api.glycosmos.org/wurcs2image/latest/png/binary/G17927IW |
GlyCosmos15-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 483-494 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | chondroitin | http://www.glycoepitope.jp/epitopes/EP0081 |
T2 | 668-683 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | heparan sulfate | http://www.glycoepitope.jp/epitopes/EP0086 |
T3 | 2057-2068 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | chondroitin | http://www.glycoepitope.jp/epitopes/EP0081 |
Lectin-Jamboree-Sentence
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-63 | Sentence | denotes | Identification of a novel glycosaminoglycan core-like molecule. |
T2 | 64-67 | Sentence | denotes | II. |
T3 | 68-129 | Sentence | denotes | Alpha-GalNAc-capped xylosides can be made by many cell types. |
T4 | 130-414 | Sentence | denotes | The accompanying article (Manzi, A., Salimath, P. V., Spiro, R. C., Keifer, P. A., and Freeze, H. H. (1995) J. Biol. Chem. 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU). |
T5 | 415-691 | Sentence | denotes | The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-Gal-NAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains. |
T6 | 692-829 | Sentence | denotes | In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides. |
T7 | 830-1116 | Sentence | denotes | The [6-3H]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc. Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. |
T8 | 1117-1322 | Sentence | denotes | The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. |
T9 | 1323-1586 | Sentence | denotes | This novel oligosaccharide accounts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 microM Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%. |
T10 | 1587-1695 | Sentence | denotes | In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. |
T11 | 1696-1871 | Sentence | denotes | Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact. |
T12 | 1872-1979 | Sentence | denotes | This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis. |
T13 | 1980-2188 | Sentence | denotes | Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation. |
NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 329-334 | OrganismTaxon | denotes | human | 9606 |
T2 | 733-738 | OrganismTaxon | denotes | human | 9606 |
T3 | 761-776 | OrganismTaxon | denotes | Chinese hamster | 10029 |
T4 | 933-946 | OrganismTaxon | denotes | Helix pomatia | 6536 |
T5 | 1410-1415 | OrganismTaxon | denotes | human | 9606 |
T6 | 1429-1444 | OrganismTaxon | denotes | Chinese hamster | 10029 |
Anatomy-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 777-782 | Body_part | denotes | ovary | http://purl.obolibrary.org/obo/UBERON_0000992 |
T2 | 933-938 | Body_part | denotes | Helix | http://purl.obolibrary.org/obo/UBERON_0002488 |
T3 | 1445-1450 | Body_part | denotes | ovary | http://purl.obolibrary.org/obo/UBERON_0000992 |
HP-phenotype
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 335-343 | Phenotype | denotes | melanoma | HP:0002861 |
T2 | 739-745 | Phenotype | denotes | cancer | HP:0002664 |
T3 | 1416-1424 | Phenotype | denotes | melanoma | HP:0002861 |
CL-cell
Id | Subject | Object | Predicate | Lexical cue | cl_id |
---|---|---|---|---|---|
T1 | 739-750 | Cell | denotes | cancer cell | http://purl.obolibrary.org/obo/CL:0001064 |